IBEC signs an agreement with ICMS of TU Eindhoven to foster their collaboration Blog Post

The Institute for Bioengineering of Catalonia (IBEC), based in the Barcelona Science Park, and the Institute of Complex Molecular Systems (ICMS) at Eindhoven University of Technology, have signed the first agreement between the two institutes to foster their collaboration. This institutional alliance will allow to share resources, knowledge and provide mobility programs.

 

Droplite and New Born Solutions, winners of the Chemostart Acceleration Programme Blog Post

Droplite and New Born Solutions, with office at the Barcelona Science Park, have been selected to participate in the ChemoStart Programme, an initiative from the Insud Pharma pharmaceutic group, that looks for promoting innovation and disruptive projects that help improving health and well-being of people. Both startups, with VB Devices –also winner of this third edition- will get support to improve their health solutions in internationalization, marketing, scalability or business commercialization.

 

Esteve acquires German pharmaceutical company Riemser and expands its presence in Europe Blog Post

Esteve have come to an agreement to acquire the German pharmaceutical company Riemser. Headquartered in Berlin, Riemser has subsidiaries in the United Kingdom, France, and Spain and is present in nearly 50 countries through alliances with third parties. This acquisition provides Esteve ––which has its Drug Discovery and Preclinical Development Center at the Barcelona Science Park–– with greater pharmaceutical presence in Europe’s main markets and a portfolio of proprietary specialty products for hospital use. 

 

Researchers from the CNAG-CRG develop a new classification system for tumours Blog Post

Based on the largest study of cancer patients of its kind, scientists at the Centre Nacional d’Anàlisi Genòmica (CNAG-CRG), located in the Barcelona Science Park, have created a new way of classifying tumours. Clinicians can use genome sequencing to assign their patients’ tumours to one of sixteen groups in the new classification system, ten of which provide important information for the diagnosis and treatment of the disease, like whether an individual will respond to immunotherapy. The work is published in PLOS Computational Biology.

 

The University of Barcelona bestows an accolade on Esteve Blog Post

In an event held in the Great Hall of the Historic Building of the University of Barcelona, Esteve Pharmaceuticals received an accolade for its long history of collaboration in research, development and innovation. The pharmaceutical group –which has its Drug Discovery and Preclinical Development Center at the Barcelona Science Park– sees recognized his commitment to collaborative innovation to provide solutions to medical needs of high social impact.

 

Nostrum Biodiscovery wins the 2019 of Senén Vilaró Prize for best innovative company Blog Post

Nostrum Biodiscovery (NBD), located at the Barcelona Science Park, has won the “2019 Senén Vilaró Prize for best innovative company”, one of the four awards conferred by the Board of Trustees of the University of Barcelona (UB) and the Bosch i Gimpera Foundation (FBG). The ceremony for the awards was held yesterday at the Aula Magna of the Historical Building of the UB.

 

A research team develop biotransistors able to hear small beats of live Blog Post

Researchers at the Institute for Bioengineering of Catalonia (IBEC) in the Barcelona Science Park, in collaboration with the Institute of Materials Science of Barcelona (ICMAB-CSIC), develop a flexible, cheap and biocompatible transistor platform able to record an electrocardiogram of cells and micro-tissues during long periods of time.The platform, based on organic transistor technology (EGOFET), can also measure the effect of drugs on beating cells, as cardiomyocytes, opening the door to several applications such as implantable devices for health.

 

Droplite gets €236,000 from the Neotec programme and the European Commission’s Seal of Excellence Blog Post

DROPLITE, a spin-off from the Institute of Photonic Sciences (ICFO) located in the Barcelona Science Park (PCB), has won a €236,000 grant from the Centre for the Development of Industrial Technology (CDTI) in the latest NEOTEC. The company has also earned the European Commission’s Seal of Excellence, which is awarded to start-ups that have first-class innovation ideas with great potential to open up new markets.

 

Aerie Pharmaceuticals announces agreement to acquire Avizorex Pharma for $10 Million Blog Post

La farmacèutica Aerie Pharmaceuticals, que cotitza al Nasqad, ha annunciat l’adquisició d’Avizorex Pharma (AVX Pharma), amb seu al Parc Científic de Barcelona, per un import de 10 millones de dòlares. La companyia, fundada l’any 2013 com a spin-off de la Universitat Miguel Hernandez de Elche (UMH) per l’emprenedor Patrick Tresserras i el professor Carlos Belmonte de l’Institut de Neurociencias (UMH -CSIC), està especialitzada en el desenvolupament de teràpies innovadores per a la síndrome d’ull sec.